Table 1 Respondent demographics and characteristics
Respondents (N=8,000) | |
|---|---|
Sex, n (%) | |
Female | 4,918 (61.5) |
Male | 3,082 (38.5) |
Age, years | 34.7 |
Age range, years, n (%) | |
18–25 | 1,540 (19.3) |
26–35 | 2,697 (33.7) |
36–40 | 1,372 (17.2) |
41–50 | 2,391 (29.9) |
Country, n (%) | |
France | 1,024 (12.8) |
Spain | 1,020 (12.8) |
Italy | 1,014 (12.7) |
Germany | 1,000 (12.5) |
UK | 1,000 (12.5) |
Netherlands | 855 (10.7) |
Sweden | 603 (7.5) |
Finland | 473 (5.9) |
Austria | 468 (5.9) |
Belgium | 303 (3.8) |
Norway | 240 (3.0) |
Years since asthma diagnosis, n (%)a | |
1 or less | 233 (3.3) |
2–5 | 777 (11.0) |
6–10 | 1,069 (15.1) |
11 or more | 5,014 (70.7) |
Current smokers, bn (%) | 1,820 (22.8) |
Co-morbidities,c n (%) | |
Depression | 1,083 (13.5) |
High BP/hypertension | 1,210 (15.1) |
Diabetes | 870 (10.9) |
Rheumatoid arthritis | 670 (8.4) |
COPD | 493 (6.2) |
Heart disease | 426 (5.3) |
Cancer | 221 (2.8) |
Treatment type,d n (%) | |
None | 359 (7.7) |
Reliever inhaler only | 1,419 (30.3) |
Single-drug preventer inhaler (±reliever inhaler) | 1,923 (41.0) |
Combination preventer inhaler (±reliever inhaler) | 754 (16.1) |
Combination preventer inhaler plus oral pill (±reliever inhaler) | 234 (5.0) |